Proton and Carbon-Ion Therapy in China: Patient Guide

Compare proton, carbon-ion and photon plans in China by evidence, range and RBE uncertainty, centre licensing, quality control, side effects, records and cost.

Key takeaways

Protons and carbon ions can put most of their dose at a planned depth and cut the exit dose behind the tumour. A prettier dose distribution, though, does not by itself mean longer survival or fewer side effects [4].
Carbon ions differ from protons in biology as well as physics. Their relative biological effectiveness comes out of a model and changes along the beam path, so two carbon prescriptions cannot be compared by the numbers alone [8].
The question worth asking is narrow: does a particle plan offer a real advantage over a good photon plan for this tumour, this anatomy, this motion pattern and this radiation history?
Particle therapy treats one site. It does nothing about distant metastases that have not been found yet, and when surgery or systemic therapy is needed, it cannot stand in for them.
In China these systems are Class A large medical equipment under national management, and clinical use comes with requirements on the institution, its staff, multidisciplinary review and quality control [1][2].

Full guide

Most patients first meet particle therapy as a diagram: the particle beam stops inside the tumour while the X-ray beam keeps going through the body. The physics in that picture is real. The clinical decision around it is messier. A tumour has volume, motion and a margin of microscopic risk; every beam passes through normal tissue on the way in; biological effect and range have to be modelled; and the chosen plan must be delivered accurately session after session.

Particle therapy is external-beam radiotherapy delivered with a different beam. It kills tumour cells the same way photons do, by damaging their DNA. Nothing circulates through the body like a drug, and after an ordinary session the patient is not radioactive.

Proton and carbon-ion therapy are not interchangeable

Feature	Proton therapy	Carbon-ion therapy
Charged particle	hydrogen nucleus	heavier carbon nucleus
Physical aim	concentrate dose near the Bragg peak and reduce dose beyond the target	similar finite-range advantage with different lateral and fragmentation characteristics
Biological effect	commonly planned with a clinical RBE convention, while biological uncertainty still exists	higher-LET effect varies with depth, tissue and model; centre-specific RBE modelling matters
Evidence base	broader use and more comparative trials in selected diseases	fewer centres, more single-centre or non-randomised data; comparative evidence remains limited for many indications
Typical decision	whether normal-tissue sparing justifies it over modern photons	whether both physical and biological rationale justify it over photons or protons

The National Cancer Institute describes the main proton advantage as less radiation delivered beyond the tumour — and in the same breath points out that trials are still comparing protons with photons [4]. Carbon ions ionise more densely and may hit harder biologically, but they hit normal tissue too. Centres do not all use the same RBE model, so a carbon prescription written in Gy(RBE) is not a plain physical dose, and it does not carry directly from one institution to another [8].

Ask for three plans, not three slogans

When the choice is genuinely uncertain, the comparison that tells you the most is usually:

a current photon plan, usually IMRT or VMAT;
a proton plan built on the technique that centre can actually deliver;
a carbon-ion plan, if carbon therapy makes clinical sense here and is available.

Insist that all three use the same target volumes, the same prescription goal and the same organ-at-risk constraints. Then look past the colourful dose clouds and ask for dose–volume numbers on the structures that actually drive this patient’s risk: brainstem, optic pathways, spinal cord, cochlea, heart, lungs, bowel, kidneys, bone marrow or growth plates, depending on the case.

One plan may wash a large body volume in less low-dose radiation yet barely change the peak dose to the structure that limits treatment. Another may spare one organ and, in exchange, become more sensitive to range or motion. Someone has to translate that into clinical terms, so ask the radiation oncologist and the medical physicist which difference is big enough to matter.

Where a strong rationale may exist

Particle therapy earns its keep when a high dose has to sit right next to a critical organ, when the total dose to the body matters most, or when earlier radiation has used up the normal-tissue reserve. Typical examples: selected paediatric cancers, skull-base chordoma or chondrosarcoma, ocular or central nervous system tumours, some head-and-neck or paraspinal tumours, and carefully chosen reirradiation. None of these means automatic eligibility.

Age, pathology, target geometry, curative or palliative intent, expected survival, prior surgery, systemic therapy, metastatic burden, even the ability to lie in the same position every day — each of these shifts the balance. A widely metastatic cancer is usually threatened by something local dose shaping cannot reach. A small superficial target may already have an excellent photon or electron plan.

Dosimetry and clinical benefit are different levels of evidence

The randomised trials so far show why both deserve a hearing.

In locally advanced oesophageal cancer, a phase II randomised trial found a lower total toxicity burden with protons than with IMRT, while three-year progression-free and overall survival came out similar [6]. That is a real toxicity benefit in the pathway tested. It does not show that protons extend survival, and it does not mean every oesophageal plan gains the same amount.

The adaptive randomised trial in locally advanced non-small-cell lung cancer went the other way on dosimetry: passive-scattering protons improved several cardiac dose measures, yet the prespecified endpoints — severe radiation pneumonitis and local failure — were no better than with IMRT [7]. And technique, planning and the learning curve were all still moving during the study.

Carbon-ion evidence is narrower still, indication by indication. In the 2024 ISAC randomised phase II trial for inoperable or incompletely resected sacrococcygeal chordoma, the proton and carbon-ion arms showed no significant outcome difference; local control did not hold up as well as hoped, and grade 4 wound-healing events occurred [9]. A systematic review of charged particles for spinal and sacral chordoma/sarcoma found mostly lower-level, high-bias evidence and asked for direct comparisons [10]. Promising and proven superior are two different words.

Range, motion and anatomy can change the delivered dose

A charged particle stops where the material in its path tells it to stop. Air cavities, bowel gas, dental metal, a shrinking tumour, weight loss, fluid, inflammation and small differences in daily set-up can all move the endpoint. Breathing and organ motion make the chest and upper abdomen harder still. A beam that looks beautifully shaped on the planning CT can turn fragile once the anatomy shifts.

It is fair to ask how the centre handles:

four-dimensional CT and respiratory motion;
immobilisation, and image guidance at every fraction;
robust optimisation and range-uncertainty margins;
dental artefact, implants and cavities that change;
repeat CT and replanning, whether scheduled or triggered;
machine downtime and treatment interruptions;
independent plan checks and patient-specific quality assurance.

China’s WS 816—2023 standard, in force since March 2024, covers quality-control testing for medical proton and heavy-ion equipment [3]. Passing equipment QA says nothing by itself about patient-specific planning, verification and clinical review; those are separate responsibilities.

Reirradiation needs the first course, not a verbal summary

If you have had radiotherapy before, bring the original DICOM RT plan, structure set, dose and treatment record. A discharge note that says “received 60 Gy” is not enough. The new team has to reconstruct the cumulative dose to critical organs, account for the different fraction sizes and estimate how much uncertainty the anatomical change adds.

A particle plan can limit the new dose to some tissue; it cannot undo the injury already there. Necrosis, vascular injury, fracture, neuropathy, fistula and poor wound healing all remain possible. Ask the centre to spell out which prior records are missing, what assumptions it worked with and how that uncertainty is reflected in the consent discussion.

How to verify a Chinese particle centre

China’s 2023 equipment catalogue puts heavy-ion and proton radiotherapy systems in Class A — large medical equipment managed at national level [1]. The 2022 clinical-application standard then requires an institution with comprehensive cancer-care capability, trained radiation oncologists and physicists, multidisciplinary decision-making, informed consent and quality systems [2].

Then ask for evidence that fits the exact site and the current service:

the institution’s equipment configuration/use authorisation, plus its radiation-practice permissions;
whether the proton or carbon room treats patients routinely or is still commissioning a new service;
the named radiation oncologist and physicist, and their particle experience in this disease;
how many patients a year they treat with this disease and this technique;
access to pathology, surgery, medical oncology, imaging, anaesthesia and emergency care;
machine uptime, backup arrangements, and the rule for switching to photons if an outage drags on;
whether outcomes and toxicity are reviewed prospectively.

A licence to own the machine proves neither patient selection nor plan quality.

The treatment pathway is longer than beam-on time

The workflow usually runs through pathology and staging review, multidisciplinary discussion, immobilisation, a planning CT (sometimes with MRI or PET fusion and four-dimensional imaging), contouring, plan optimisation, physics checks, image-guided fractions and scheduled reviews during treatment. Depending on the site, you may also need a custom mask, body mould, bite block or motion device.

Get the expected number of fractions, the days between simulation and first treatment, any planned breaks, the review schedule and the criteria for replanning. A shorter carbon-ion course is not automatically gentler biologically or safer; dose per fraction, RBE model, target and normal tissues all enter that calculation.

Side effects follow the treated anatomy

No single “proton side-effect list” exists, because the side effects belong to the anatomy being treated. Acute effects can include fatigue, skin reaction, mucosal inflammation, swallowing difficulty, nausea, diarrhoea, urinary symptoms, marrow suppression or site-specific pain. Late effects can include fibrosis, endocrine dysfunction, organ injury, vascular effects, neuropathy, fracture, impaired growth, cognitive or sensory change and second malignancy.

Less dose to normal tissue may cut some of these risks, which matters most when long survival gives late effects time to appear. Even so, every beam has an entrance dose, every plan carries uncertainty, and biological injury cannot be modelled away. Ask for absolute risk estimates for the organs in your plan, and for the centre’s follow-up schedule.

Cross-border cost and timing questions

Ask for the costs as separate line items: medical review, pathology and imaging review, simulation, immobilisation, planning, each fraction, image guidance, anaesthesia if required, medicines, accommodation, replanning, follow-up. Then pin down what happens to your money if the final plan shows little advantage, if the patient turns out ineligible, if the machine stops or if treatment has to switch to photons.

Hold off on any non-refundable stay until the review is more than a marketing exercise. A provisional opinion cannot confirm deliverability until the images, pathology, staging, previous radiation and simulation are all adequate. Before leaving China, collect the treatment summary, the prescription and delivered fractions, the planning report, dose–volume information, the toxicity record, the follow-up plan and — where transferable — the DICOM RT dataset.

Medical disclaimer: This guide cannot tell you whether proton or carbon-ion therapy is appropriate for you. That choice depends on pathology, staging, complete imaging, a comparison with the other treatments and a deliverable radiation plan reviewed by qualified specialists.

FAQ

Does no exit dose mean no side effects?

No. Every beam has an entrance dose, the target volume includes nearby tissue, and range and motion uncertainty never fully disappear. What you actually experience depends on the organ, the total and fraction dose, any prior treatment and the plan itself.

Is proton therapy always better for children?

Lower integral dose matters a great deal for growing tissues and for children with decades of life ahead. Even so, the indication, the anaesthesia needs, motion, the target and the available photon plan all have to be compared case by case.

How can I compare two centres’ quotations?

Line them up on the specifics: the exact particle and technique, the number of fractions, what planning and imaging are included, clinician and physicist review, replanning, how interruptions are handled, follow-up, and the fallback if particle treatment turns out not to be deliverable.

Proton and Carbon-Ion Therapy in China: A Patient Guide